Overview

Phase I Study to Investigate the Safety and Efficacy of HBV DNA Vaccine

Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and immunogenicity of a novel mixed plasmid DNA (HB-110) combined with an antiviral agent (Adefovir) for the patients with chronic Hepatitis B infection.
Phase:
Phase 1
Details
Lead Sponsor:
Genexine, Inc.
Treatments:
Adefovir
Adefovir dipivoxil